Skip to main content
Erschienen in: Die Nephrologie 5/2023

02.08.2023 | Chronische Nierenerkrankung | Arzneimitteltherapie

Vitamin-D-Therapie: Wer braucht Calcifediol?

verfasst von: Prof. Dr. med. Helga Frank, MHBA

Erschienen in: Die Nephrologie | Ausgabe 5/2023

Einloggen, um Zugang zu erhalten

Auszug

Die Entwicklung einer CKD-MBD („chronic kidney disease – mineral and bone disorder“) ist eine typische Sekundärfolge bei chronischer Nierenerkrankung (CKD) mit ernsten Folgen für die Morbidität und Mortalität nierenkranker Patienten. …
Literatur
4.
Zurück zum Zitat Khan S (2007) Secondary hyperparathyroidism is associated with higher cost of care among chronic kidney disease patients with cardiovascular comorbidities. Nephron Clin Pract 105:c159–c164 CrossRefPubMed Khan S (2007) Secondary hyperparathyroidism is associated with higher cost of care among chronic kidney disease patients with cardiovascular comorbidities. Nephron Clin Pract 105:c159–c164 CrossRefPubMed
6.
Zurück zum Zitat Cunningham J et al (2011) Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 6:913–921 CrossRefPubMed Cunningham J et al (2011) Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 6:913–921 CrossRefPubMed
7.
Zurück zum Zitat Ravani P et al (2009) Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 75:89–95 CrossRef Ravani P et al (2009) Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 75:89–95 CrossRef
8.
Zurück zum Zitat Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM, Endocrine Society (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1911–1930 CrossRefPubMed Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM, Endocrine Society (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1911–1930 CrossRefPubMed
9.
Zurück zum Zitat National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(4):1–201 National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(4):1–201
10.
Zurück zum Zitat Sprague SM et al (2017) Poster presented at Kidney Week 2017, Oct 31–Nov 5, 2017, New Orleans (USA abstract TH-PO515) Sprague SM et al (2017) Poster presented at Kidney Week 2017, Oct 31–Nov 5, 2017, New Orleans (USA abstract TH-PO515)
11.
Zurück zum Zitat Strugnell SA, Sprague SM, Ashfaq A, Petkovich M, Bishop CW (2019) Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease. Am J Nephrol 49(4):284–293 CrossRefPubMed Strugnell SA, Sprague SM, Ashfaq A, Petkovich M, Bishop CW (2019) Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease. Am J Nephrol 49(4):284–293 CrossRefPubMed
14.
Zurück zum Zitat Sprague SM, Silva AL, Al-Saghir F, Damle R, Tabash SP, Petkovich M, Messner EJ, White JA, Melnick JZ, Bishop CW (2014) Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease. Am J Nephrol 40:535–545 CrossRefPubMed Sprague SM, Silva AL, Al-Saghir F, Damle R, Tabash SP, Petkovich M, Messner EJ, White JA, Melnick JZ, Bishop CW (2014) Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease. Am J Nephrol 40:535–545 CrossRefPubMed
15.
Zurück zum Zitat Sprague SM et al (2016) Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease. Am J Nephrol 44:316–325 CrossRefPubMed Sprague SM et al (2016) Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease. Am J Nephrol 44:316–325 CrossRefPubMed
17.
Zurück zum Zitat Cozzolino M, Minghetti P, Navarra P (2022) Extended-release calcifediol in stage 3–4 chronic kidney disease: a new therapy for the treatment of secondary hyperparathyroidismassociated with hypovitaminosis D. J Nephrol 35:863–873 CrossRefPubMed Cozzolino M, Minghetti P, Navarra P (2022) Extended-release calcifediol in stage 3–4 chronic kidney disease: a new therapy for the treatment of secondary hyperparathyroidismassociated with hypovitaminosis D. J Nephrol 35:863–873 CrossRefPubMed
18.
Zurück zum Zitat Sprague SM et al (2017) Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease. Exp Rev. Endocrinol Metab 12:289–301 CrossRef Sprague SM et al (2017) Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease. Exp Rev. Endocrinol Metab 12:289–301 CrossRef
19.
Zurück zum Zitat Chertow GM et al (2012) Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367:2482–2494 (& Supplementary Appendix) CrossRefPubMed Chertow GM et al (2012) Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367:2482–2494 (& Supplementary Appendix) CrossRefPubMed
20.
Zurück zum Zitat Moe SM et al (2015) Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation 132:27–39 CrossRefPubMed Moe SM et al (2015) Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation 132:27–39 CrossRefPubMed
21.
Zurück zum Zitat Block GA et al (2017) Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. JAMA 317:156–164 CrossRefPubMed Block GA et al (2017) Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. JAMA 317:156–164 CrossRefPubMed
22.
Zurück zum Zitat Agarwal R, Georgianos PI (2016) Con: Nutritional vitamin D replacement in chronic kidney disease and end-stage renal disease. Nephrol Dial Transplant 31:706–713 CrossRefPubMed Agarwal R, Georgianos PI (2016) Con: Nutritional vitamin D replacement in chronic kidney disease and end-stage renal disease. Nephrol Dial Transplant 31:706–713 CrossRefPubMed
23.
Zurück zum Zitat Martínez-Arias L, Panizo S, Alonso-Montes C, Martín-Vírgala J, Martín-Carro B, Fernández-Villabrille S, García Gil-Albert C, Palomo-Antequera C, Fernández-Martín JL, Ruiz-Torres MP, Dusso AS, Carrillo-López N, Cannata-Andía JB, Naves-Díaz M (2021) Effects of calcitriol and paricalcitol on renal fibrosis in CKD. Nephrol Dial Transplant 36(5):793–803. https://​doi.​org/​10.​1093/​ndt/​gfaa373 CrossRefPubMed Martínez-Arias L, Panizo S, Alonso-Montes C, Martín-Vírgala J, Martín-Carro B, Fernández-Villabrille S, García Gil-Albert C, Palomo-Antequera C, Fernández-Martín JL, Ruiz-Torres MP, Dusso AS, Carrillo-López N, Cannata-Andía JB, Naves-Díaz M (2021) Effects of calcitriol and paricalcitol on renal fibrosis in CKD. Nephrol Dial Transplant 36(5):793–803. https://​doi.​org/​10.​1093/​ndt/​gfaa373 CrossRefPubMed
24.
Zurück zum Zitat Bover J, Gunnarsson J, Csomor P, Kaiser E, Cianciolo G, Lauppe R (2021) Impact of nutritional vitamin D supplementation on parathyroid hormone and 25-hydroxyvitamin D levels in non-dialysis chronic kidney disease: a meta-analysis. Clin Kidney J 14(10):2177–2186. doi: 10.1093/ckj/sfab035 CrossRefPubMedPubMedCentral Bover J, Gunnarsson J, Csomor P, Kaiser E, Cianciolo G, Lauppe R (2021) Impact of nutritional vitamin D supplementation on parathyroid hormone and 25-hydroxyvitamin D levels in non-dialysis chronic kidney disease: a meta-analysis. Clin Kidney J 14(10):2177–2186. doi: 10.1093/ckj/sfab035 CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Westerberg P‑A et al (2018) High doses of cholecalciferol alleviate the progression of hyperparathyroidism in patients with CKD Stages 3-4: results of a 12-week double-blind, randomized, controlled study. Nephrol Dial Transplant 33:466–471 CrossRefPubMed Westerberg P‑A et al (2018) High doses of cholecalciferol alleviate the progression of hyperparathyroidism in patients with CKD Stages 3-4: results of a 12-week double-blind, randomized, controlled study. Nephrol Dial Transplant 33:466–471 CrossRefPubMed
26.
Zurück zum Zitat Cozzolino M, Ketteler M (2019) Evaluating extended-release calcifediol as a treatment option for chronic kidney disease-mineral and bone disorder (CKD-MBD). Expert Opin Pharmacother 20:2081–2093 CrossRefPubMed Cozzolino M, Ketteler M (2019) Evaluating extended-release calcifediol as a treatment option for chronic kidney disease-mineral and bone disorder (CKD-MBD). Expert Opin Pharmacother 20:2081–2093 CrossRefPubMed
27.
Zurück zum Zitat Fadda G (2020) Poster presented at National Kidney Foundation (NKF) Virtual Congress, 26–29 March 2020 (Poster #206) Fadda G (2020) Poster presented at National Kidney Foundation (NKF) Virtual Congress, 26–29 March 2020 (Poster #206)
Metadaten
Titel
Vitamin-D-Therapie: Wer braucht Calcifediol?
verfasst von
Prof. Dr. med. Helga Frank, MHBA
Publikationsdatum
02.08.2023
Verlag
Springer Medizin
Erschienen in
Die Nephrologie / Ausgabe 5/2023
Print ISSN: 2731-7463
Elektronische ISSN: 2731-7471
DOI
https://doi.org/10.1007/s11560-023-00677-z

Weitere Artikel der Ausgabe 5/2023

Die Nephrologie 5/2023 Zur Ausgabe

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.